Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$1.2 - $1.53 $559 - $712
466 Added 0.63%
74,560 $111,000
Q4 2022

Feb 14, 2023

BUY
$1.02 - $1.5 $75,575 - $111,141
74,094 New
74,094 $86,000
Q2 2022

Aug 15, 2022

BUY
$1.12 - $1.61 $31,110 - $44,720
27,777 New
27,777 $44,000
Q1 2022

May 16, 2022

SELL
$1.21 - $2.48 $17,252 - $35,359
-14,258 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$1.84 - $2.68 $26,234 - $38,211
14,258 New
14,258 $35,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $109M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.